Journal of Diagnostics Concepts & Practice >
Analysis of relationship between gene status (EGFR, ALK, ROS1)and clinicopathological features in 1 232 cases of lung adenocarcinoma with lesion of maximum diameter≤1 cm
Received date: 2023-07-11
Online published: 2024-05-30
Objective To study relationship between gene status [epidermal growth factor receptor(EGFR), anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1, receptor tyrosine kinase (ROS1)] in cases with pathological lung adenocarcinoma lesion of maximum diameter ≤1 cm. Methods A total of 1 232 patients with lung adenocarcinoma lesion of maximum diameter ≤1 cm were enrolled in the Pathology department of Huadong Hospital from January 2013 to October 2020. For patients with multiple lesions, only the biggest lesion was selected. The gene status of EGFR, ALK and ROS1 were identified and clinicopathological characteristics were retrospectively analyzed. Results There were 387 males and 845 females,with a mean age of 54 years.There were 182 (14.8%) cases of adenocarcinomas in situ, 778 (63.1%) cases of minimal invasive adenocarcinomas, 249(20.2%) invasive non-mucinous adenocarcinomas, and 23 (1.9%) invasive mucinous adenocarcinomas. It revealed that 43.1% (352/817 cases) had EGFR gene mutations, of which 46.9% (165/352 cases) were 21L858R mutations and 40.6% (143/352 cases) were 19Del mutations, and 0.9% (3/352 cases) were 18G719X/20S768I and 21L858R/20S768I double mutations. The rate of EGFR mutation were 31.0% (40/129), 42.0% (208/495), 58.4% (104/178), and 0 (0/15) for adenocarcinoma in situ, minimal invasive adenocarcinoma, invasive non-mucinous adenocarcinoma, and invasive mucinous adenocarcinoma, respectively.And 23.1% (3/13 cases) had different EGFR mutation detected for different lesions in the same patient (In 13 cases with 2 lesions of lung adenocarcinoma successively, 2 cases were positive for 19Del mutation in the first postoperative lesion and EGFR wild-type in the second lesion: one case was EGFR wild type in the first postoperative lesion and 21L858R mutation in the second lesion). The rate of EGFR mutations was correlated with histological type and age, and not associated with sex or smoking. EGFR mutations was more likely to occur in the age group over 60 years and in invasive non-mucinous adenocarcinomas. It showed that 1.9% (22/1168 cases) were positive for ALK rearrangements, with a positive rate of 5.2% in invasive non-mucinous adenocarcinomas and of 2.6% in patients ≤60 years. The positive rate of ALK rearrangement in adenocarcinomas with solid components (22.2%, 4/18) was significantly higher than that in invasive non-mucinous adenocarcinomas (5.2%, 12/233) and adenocarcinomas without solid components (1.1%, 12/1095). It showed that 0.8% (6/795 cases) were positive for ROS1 rearrangements, independent of sex, age, smoking and histological type. A total of 382 cases were tested for EGFR, ALK and ROS1 simultaneously, of which 40.6% (155/382) of the tumours containing one of these three mutations or rearrangements status, and no co-exist in either or all three. Conclusions In this single-center study, minimal invasive adenocarcinomas accounts for the majority (63.1%) of lung adenocarcinomas with a lesion size ≤1 cm. At least 40% of them have mutations or rearrangements in one of the three genes (EGFR, ALK and ROS1), and none of which were significantly associated with sex or smoking. The most common EGFR mutations are 21L858R and 19Del, which occur more frequently in invasive non-mucinous adenocarcinomas in the >60 age group, while ALK rearrangements occur more frequently in solid-component adenocarcinomas in the ≤60 age group. The incidence of ROS1 rearrangements is low. The molecular change may be different in the same patien to with multiple adenocarcinomas,molecular testing foci is necessary for each lesion.
ZHU Xia, WANG Xin, JIN Jingjing, XIAO Li . Analysis of relationship between gene status (EGFR, ALK, ROS1)and clinicopathological features in 1 232 cases of lung adenocarcinoma with lesion of maximum diameter≤1 cm[J]. Journal of Diagnostics Concepts & Practice, 2024 , 23(01) : 57 -66 . DOI: 10.16150/j.1671-2870.2024.01.008
[1] | SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. |
[2] | CAO W, CHEN H D, YU Y W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7):783-791. |
[3] | 王泽洲, 郑莹. 1990年至2020年间全球及我国肺癌的发病流行趋势及防控措施[J]. 诊断学理论与实践, 2023, 22(01): 1-7. |
WANG Z Z, ZHENG Y. Lung cancer worldwide and in China from 1990 to 2020: prevalence and prevention measures[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(01):1-7. | |
[4] | ZHUANG X, ZHAO C, LI J, et al. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF[J]. Cancer Med, 2019, 8(6):2858-2866. |
[5] | DU X, SHAO Y, QIN H F, et al. ALK-rearrangement in non-small-cell lung cancer (NSCLC)[J]. Thorac Cancer, 2018, 9(4):423-430. |
[6] | LIN J J, SHAW A T. Recent Advances in Targeting ROS1 in Lung Cancer[J]. J Thorac Oncol, 2017, 12(11):1611-1625. |
[7] | CHAPMAN A M, SUN K Y, RUESTOW P, et al. Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers[J]. Lung Cancer, 2016,102:122-134. |
[8] | ARTEAGA C L, ENGELMAN J A. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics[J]. Cancer Cell, 2014, 25(3):282-303. |
[9] | DEARDEN S, STEVENS J, WU Y L, et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)[J]. Ann Oncol, 2013, 24(9):2371-2376. |
[10] | SHI Y, LI J, ZHANG S, et al. Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology - mainland China subset analysis of the PIONEER study[J]. PLoS One, 2015, 10(11):e0143515. |
[11] | TSAO A S, SCAGLIOTTI G V, BUNN P A, et al. Scientific advances in lung cancer 2015[J]. Journal of Thoracic Oncology, 2016, 11(5):613-638. |
[12] | 贺佳子, 黄清洁, 李莉, 等. 396例非小细胞肺癌EGFR,KRAS,ALK和BRAF基因突变状态及其临床病理特征[J]. 临床与病理杂志, 2020, 40(09):2252-2258. |
HE J Z, HUANG Q J, LI L, et al. Mutation status of EGFR, KRAS, ALK and BRAF genes and their clinicopathological characteristics in 396 patients with non-small cell lung cancer[J]. J Clin Pathol Res, 2020, 40(09):2252-2258. | |
[13] | 眭玉霞, 邓晓宇, 伍铮, 等. 非小细胞肺癌驱动基因突变与临床病理特征的关系[J]. 临床与实验病理学杂志, 2020, 36(09):1023-1028. |
SUI Y X, DENG X Y, WU Z, et al. Comprehensive investigation of driver gene expression and clinicopathological characteristics in non-small cell lung cancer[J]. J Clin Pathol Res, 2020, 36(09):1023-1028. | |
[14] | STEWART E L, TAN S Z, LIU G, et al. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review[J]. Transl Lung Cancer Res, 2015, 4(1):67-81. |
[15] | KOBAYASHI S, CANEPA H M, BAILEY A S, et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors[J]. J Thorac Oncol, 2013, 8(1):45-51. |
[16] | DUYSTER J, BAI R Y, MORRIS S W. Translocations involving anaplastic lymphoma kinase (ALK)[J]. Oncogene, 2001, 20(40):5623-5637. |
[17] | MOTEGI A, FUJIMOTO J, KOTANI M, et al. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth[J]. J Cell Sci, 2004, 117(Pt 15):3319-3329. |
[18] | IWAHARA T, FUJIMOTO J, WEN D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system[J]. Oncogene, 1997, 14(4):439-449. |
[19] | DEVARAKONDA S, MORGENSZTERN D, GOVINDAN R. Genomic alterations in lung adenocarcinoma[J]. Lancet Oncol, 2015, 16(7):e342-351. |
[20] | SHAW A T, ENGELMAN J A. ALK in lung cancer: past, present, and future[J]. J Clin Oncol, 2013, 31(8):1105-1111. |
[21] | ACQUAVIVA J, WONG R, CHAREST A. The multifa-ceted roles of the receptor tyrosine kinase ROS in development and cancer[J]. Biochim Biophys Acta, 2009, 1795(1):37-52. |
[22] | RIKOVA K, GUO A, ZENG Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer[J]. Cell, 2007, 131(6):1190-1203. |
[23] | STRANSKY N, CERAMI E, SCHALM S, et al. The landscape of kinase fusions in cancer[J]. Nat Commun, 2014,5:4846. |
[24] | Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma[J]. Nature, 2014, 511(7511):543-550. |
[25] | BERGETHON K, SHAW A T, OU S H, et al. ROS1 rearrangements define a unique molecular class of lung cancers[J]. J Clin Oncol, 2012, 30(8):863-870. |
[26] | TAKEUCHI K, SODA M, TOGASHI Y, et al. RET,ROS1 and ALK fusions in lung cancer[J]. Nat Med, 2012, 18(3):378-381. |
[27] | VANSTEENKISTE J, CRINO L, DOOMS C, et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up[J]. Ann Oncol, 2014, 25(8):1462-1474. |
[28] | HIRSCH F R, SCAGLIOTTI G V, MULSHINE J L, et al. Lung cancer: current therapies and new targeted treatments[J]. Lancet, 2017, 389(10066):299-311. |
/
〈 |
|
〉 |